journal
MENU ▼
Read by QxMD icon Read
search

International Clinical Psychopharmacology

journal
https://www.readbyqxmd.com/read/28628502/placebo-response-in-trichotillomania
#1
Jon E Grant, Samuel R Chamberlain, Sarah A Redden, Brian L Odlaug, Michael van Ameringen, Darin D Dougherty, Nancy J Keuthen, Suck W Kim
Trichotillomania is a functionally impairing, often overlooked disorder with no Food and Drug Administration-approved medications indicated for its treatment. The ability of clinical trials to detect the beneficial effects of pharmacologic treatment in trichotillomania has been hampered by the high placebo response rate. Very little is known about baseline demographic and clinical characteristics that may be predictive of placebo response in such patients. Overall, 104 participants assigned to placebo were pooled from five double-blind trials conducted at three sites in the USA and Canada...
June 16, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28617681/psychotropic-drugs-prescription-in-undocumented-migrants-and-indigent-natives-in-italy
#2
Cesare Cerri, Gianfrancesco Fiorini, Silvia Bini, Antonello E Rigamonti, Nicoletta Marazzi, Alessandro Sartorio, Silvano G Cella
To evaluate psychotropic drug use in undocumented migrants and natives in the same conditions of poverty. We studied drug dispensation by a nongovernmental organization during the year 2014. Drugs were identified according to the Anatomical Chemical Therapeutic classification and their quantity was measured in defined daily doses (DDD). We determined the percentage of patients taking at least one medicine with psychotropic activity in relation to the total number of patients receiving medicines of any class...
June 14, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28598899/long-term-function-and-psychosocial-outcomes-with-venlafaxine-extended-release-75-225%C3%A2-mg-day-versus-placebo-in-the-prevent-study
#3
Koichiro Watanabe, Michael E Thase, Toshiaki Kikuchi, Takashi Tsuboi, Yuko Asami, Elizabeth Pappadopulos, Min Zhang, Matthieu Boucher, Susan Kornstein
This post-hoc analysis evaluated long-term psychosocial outcomes in patients with recurrent major depressive disorder treated with venlafaxine extended release (ER) 75-225 mg/day or placebo. Patients who responded to 10-week venlafaxine ER 75-300 mg/day treatment and maintained response through a 6-month continuation treatment were assigned randomly to venlafaxine ER or placebo maintenance-phase treatment. Data from responders to acute and continuation venlafaxine ER 75-225 mg/day treatment were analyzed during 12-month maintenance treatment while receiving venlafaxine ER of up to 225 mg/day...
June 8, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28542035/trends-and-factors-associated-with-antipsychotic-use-among-elderly-patients-with-dementia-in-taiwan-from-2005-to-2013-a-population-based-study
#4
Yu-Wen Chiu, Chih-Wan Huang, Pei-Jung Chen, Nan-Wen Yu, Hui-Ju Tsai, Chi-Shin Wu, Chia-Ming Chang
This study aimed to examine the trends and factors associated with antipsychotic prescriptions for elderly outpatients with dementia in Taiwan from 2005 to 2013. We assessed the annual prescription patterns of antipsychotic medications among elderly patients attending outpatient visits for dementia between 2005 and 2013 using the National Health Insurance Research Database in Taiwan. We also carried out logistic regression analyses to test the trends and associated factors. We found that any antipsychotic prescriptions for elderly patients making visits for dementia increased slightly, from 25...
May 24, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28542034/dopamine-d2-receptor-affinity-of-antipsychotics-in-relation-to-subjective-well-being-in-patients-with-a-psychotic-disorder
#5
Iris E de Wit, Floor A van Dijk, Carin J Meijer, Mirjam J van Tricht, Lieuwe de Haan
Dopamine D2-receptor blockade by antipsychotic medication reduces psychotic symptoms, but may reduce subjective well-being. The current study aims to further explore the relation between dopamine D2-receptor affinity and subjective well-being within a large sample of patients with psychotic disorders. Patients participated in a longitudinal naturalistic cohort study: the Genetic Risk and Outcome of Psychosis (GROUP) study. Three groups of antipsychotic medication were created on the basis of their affinity for the D2-receptor: (i) loose or partial agonistic binding, (ii) moderate binding, and (iii) tight binding...
May 24, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28538024/effects-of-vilazodone-on-suicidal-ideation-and-behavior-in-adults-with-major-depressive-disorder-or-generalized-anxiety-disorder-post-hoc-analysis-of-randomized-double-blind-placebo-controlled-trials
#6
Michael E Thase, John Edwards, Suresh Durgam, Changzheng Chen, Cheng-Tao Chang, Maju Mathews, Carl P Gommoll
Treatment-emergent suicidal ideation and behavior are ongoing concerns with antidepressants. Vilazodone, currently approved for the treatment of major depressive disorder (MDD) in adults, has also been evaluated in generalized anxiety disorder (GAD). Post-hoc analyses of vilazodone trials were carried out to examine its effects on suicidal ideation and behavior in adults with MDD or GAD. Data were pooled from vilazodone trials in MDD (four studies) and GAD (three studies). The incidence of suicide-related events was analyzed on the basis of treatment-emergent adverse event reporting and Columbia-Suicide Severity Rating Scale (C-SSRS) monitoring...
May 19, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28492411/advanced-glycation-end-products-among-patients-maintained-on-antipsychotics
#7
Samer Hammoudeh, Suhaila Ghuloum, Ziyad Mahfoud, Arij Yehya, Dennis Mook-Kanamori, Marjonneke Mook-Kanamori, Karsten Suhre, Abdulmoneim Abdulhakam, Azza Al-Mujalli, Yahya Hani, Reem El Sherbiny, Hassen Al-Amin
The aim of this study was to measure advanced glycation end products (AGEs) among participants maintained on antipsychotics using the AGE Reader and to compare them with controls from the general population. Participants maintained on antipsychotics for at least 6 months were recruited from the Psychiatry Department at Rumailah Hospital, Doha, Qatar. Healthy controls were recruited from the primary healthcare centers in Doha, Qatar. AGEs of a total of 86 participants (48 patients and 38 controls) were recorded...
May 10, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28430670/comparison-between-long-acting-injectable-aripiprazole-versus-paliperidone-palmitate-in-the-treatment-of-schizophrenia-systematic-review-and-indirect-treatment-comparison
#8
Chi-Un Pae, Sheng-Min Wang, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand, Alessandro Serretti, Robin Emsley
We investigated the relative efficacy and tolerability of aripiprazole once monthly (AOM) versus paliperidone palmitate (PP) for treating schizophrenia. Extensive databases searches on short-term, placebo-controlled, randomized studies of AOM and PP were performed. Indirect treatment comparisons were performed between the two long-acting injectable antipsychotics (LAIAs). The primary efficacy endpoint was the mean change in the Positive and Negative Syndrome Scale total score from baseline between each LAIA and placebo...
April 20, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28368900/the-effect-of-methylphenidate-on-anxiety-and-depression-symptoms-in-patients-with-asperger-syndrome-and-comorbid-attention-deficit-hyperactivity-disorder
#9
Pavel Golubchik, Michal Rapaport, Abraham Weizman
The objective of this study was to assess the response of anxiety and depression symptoms to methylphenidate (MPH) treatment in patients with Asperger syndrome (AS) combined with attention deficit/hyperactivity disorder (ADHD). A group of 12 patients with AS/ADHD, aged 8-18 years, received 12 weeks of MPH treatment. The severities of ADHD, anxiety, and depression symptoms were assessed by means of the ADHD Rating Scale (ADHD-RS), Screen for Child Anxiety Related Emotional Disorders, and the Children's Depression Inventory...
March 31, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28383309/utility-of-functioning-in-predicting-costs-of-care-for-patients-with-mood-and-anxiety-disorders-a-prospective-cohort-study
#10
Conal Twomey, Alarcos Cieza, David S Baldwin
Development of payment systems for mental health services has been hindered by limited evidence for the utility of diagnosis or symptoms in predicting costs of care. We investigated the utility of functioning information in predicting costs for patients with mood and anxiety disorders. This was a prospective cohort study involving 102 adult patients attending a tertiary referral specialist clinic for mood and anxiety disorders. The main outcome was total costs, calculated by applying unit costs to healthcare use data...
July 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28383308/antidepressant-effect-in-older-depressed-patients-the-lessons-of-two-agomelatine-trials
#11
Guy M Goodwin, Pierre Thomas, Reinhard Heun, Patrice Boyer, Françoise Picarel-Blanchot, Christian de Bodinat
The present paper reports in parallel the findings of the two phase III trials that evaluated the efficacy of agomelatine in older depressed patients. It describes how the particular methodological innovations (particularly in relation to patient selection, design and accuracy of diagnosis of depression) introduced in study 2 have improved the quality of recruitment of patients and the assay sensitivity. Study 1 lacked assay sensitivity, and among the many differences with study 2, the inclusion of unexpected mildly ill patients could have inflated the placebo response...
July 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28379882/silexan-in-generalized-anxiety-disorder-investigation-of-the-therapeutic-dosage-range-in-a-pooled-data-set
#12
Siegfried Kasper, Hans-Jürgen Möller, Hans-Peter Volz, Sandra Schläfke, Angelika Dienel
Silexan, a special active substance produced from Lavandula angustifolia, is efficacious in subsyndromal anxiety at a dose of 80 mg/day, but its effective dosage in generalized anxiety disorder (GAD) has yet to be defined. In two double-blind, placebo-controlled trials, daily doses of 10, 40, 80, and 160 mg silexan were administered for 10 weeks. A total of 925 adults with GAD according to Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria and a Hamilton Anxiety Scale (HAMA) total score of at least 18 points were analyzed for efficacy...
July 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28346296/antipsychotic-drug-use-in-nursing-home-residents-with-and-without-dementia-keep-an-eye-on-the-pro-re-nata-medication
#13
Katharina Allers, Michael Dörks, Guido Schmiemann, Falk Hoffmann
Behavioral and psychological symptoms of dementia often lead to the prescription of antipsychotics, especially in nursing homes, but their use remains controversial. This study aimed to assess antipsychotic drug use in residents with dementia compared with those without dementia. Data were obtained through the cross-sectional 'inappropriate medication in patients with renal insufficiency in nursing homes' (IMREN) study including data from 21 nursing homes. Descriptive statistics were used and factors associated with the prescription of antipsychotics were identified by logistic regression...
July 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28234656/managing-interactions-between-cognitive-enhancers-and-other-psychotropics
#14
Siu W Tang, Wayne H Tang, Brian E Leonard
Polypharmacy is common in psychiatry. Usage of cognitive enhancers is increasing in the psychiatric population. Many clinicians are not familiar with these new psychoactive compounds. This paper reviews the potential drug-drug interactions when these cognitive enhancers are used together with psychotropic drugs and their confounding effects on diagnosis and clinical management.
July 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28225439/tachycardia-in-patients-treated-with-clozapine-versus-antipsychotic-long-acting-injections
#15
Björn M Nilsson, Oscar Edström, Leif Lindström, Petter Wernegren, Robert Bodén
Tachycardia is a known adverse effect during clozapine treatment. However, prevalence reported differs widely between studies and hitherto there are no studies comparing clozapine-treated patients with a similar control group. The present study was carried out to assess the prevalence of tachycardia in patients treated with clozapine and antipsychotic long-acting injections (LAI). Data on heart rate (HR), concomitant medication, and relevant anthropometric and laboratory measurements were collected for all clozapine-treated patients (n=174) in a defined catchment area and compared with data on patients treated with LAI (n=87)...
July 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28181957/use-of-nalmefene-in-patients-with-comorbid-borderline-personality-disorder-and-alcohol-use-disorder-a-preliminary-report
#16
Ana Martín-Blanco, Barbara Patrizi, Joaquim Soler, Xero Gasol, Matilde Elices, Miquel Gasol, Cristina Carmona, Juan C Pascual
Comorbidity between borderline personality disorder (BPD) and alcohol use disorder (AUD) is high and relevant as alcohol consumption seems to worsen BPD symptomatology. One of the newest treatments for AUD, nalmefene, may be useful to improve BPD symptoms not only indirectly by reducing alcohol consumption but also directly by acting on the opioid system as this system has been related to specific BPD symptoms. This open-label study aimed at evaluating the efficacy of an 8-week nalmefene treatment in reducing alcohol consumption in individuals with BPD and comorbid AUD...
July 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28181956/extrapyramidal-symptoms-in-schizophrenia-evidence-of-blunted-cerebral-hemodynamics-during-a-planning-task
#17
Daniel Schuepbach, Matthias Michel, Gert Wagner, Stefan Duschek, Sabine C Herpertz
Acute extrapyramidal symptoms (EPS) occur frequently in schizophrenia, mostly caused by antidopaminergic substances. There have been no published reports on the impact of acute EPS on cerebral blood flow (CBF) or related measures. In the following study, we examined schizophrenic patients with and without EPS during a planning task and measurements of CBF velocity. Sixteen patients with chronic schizophrenia and 16 healthy participants performed a planning paradigm during bilateral functional transcranial Doppler sonography of the middle cerebral arteries...
July 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28252452/reduced-sexual-dysfunction-with-aripiprazole-once-monthly-versus-paliperidone-palmitate-results-from-qualify
#18
Steven G Potkin, Jean-Yves Loze, Carlos Forray, Ross A Baker, Christophe Sapin, Timothy Peters-Strickland, Maud Beillat, Anna-Greta Nylander, Peter Hertel, Henrik Steen Andersen, Anna Eramo, Karina Hansen, Dieter Naber
Sexual dysfunction, a common side effect of antipsychotic medications, may be partly caused by dopamine antagonism and elevation of prolactin. In QUALIFY, a randomized study, aripiprazole once-monthly 400 mg (AOM 400), a dopamine D2 receptor partial agonist, showed noninferiority and subsequent superiority versus paliperidone palmitate (PP), a dopamine D2 receptor antagonist, on the Heinrichs-Carpenter Quality-of-Life Scale (QLS) in patients with schizophrenia aged 18-60 years. Sexual dysfunction (Arizona Sexual Experience Scale) and serum prolactin levels were also assessed...
May 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27941358/simvastatin-adjunct-therapy-for-negative-symptoms-of-schizophrenia-a-randomized-double-blind-placebo-controlled-trial
#19
Soode Tajik-Esmaeeli, Ehsan Moazen-Zadeh, Niloofar Abbasi, Seyed V Shariat, Farzin Rezaei, Bahman Salehi, Shahin Akhondzadeh
We investigated the effects of simvastatin adjunctive therapy on the negative symptoms of schizophrenia. In this double-blind trial, inpatients with chronic schizophrenia were clinically stabilized on a constant dose of risperidone for at least 4 weeks before the study and were then randomized to receive risperidone (4-6 mg/day) plus either simvastatin (40 mg/day) (n=33) or placebo (n=33) for 8 weeks. The Positive and Negative Syndrome Scale was used to measure the negative, positive, and general symptoms of schizophrenia at baseline and every 2 weeks...
March 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27902536/patients-on-psychotropic-medications-and-herbal-supplement-combinations-clinical-considerations
#20
Siu Wa Tang, Wayne Tang, Brian E Leonard
Populations using herbs and herbal preparations are widespread and growing. As many herbal ingredients exert actions on psychotropic drug targets, psychiatrists should be well informed and aware of potential drug-drug interactions in clinical practice. Reliable and clinically useful information in this area, however, is fragmented, if not deficient. This paper reviewed the clinical aspects of herb-drug interactions, focusing in particular on the monoamine oxidase enzyme and P450 cytochrome enzyme-inhibitory properties of herbs and their potential interference with psychotropic drug actions and clinical judgement...
March 2017: International Clinical Psychopharmacology
journal
journal
29324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"